08/07/2019 – AB Science annonce la publication de l’étude positive de phase 2/3 du masitinib dans la SLA dans la revue Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
